A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
Authors
Keywords
PNT2258, Phase I, DNAi, Deoxyribonucleic acid inhibitor, BCL2, Liposome
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 73, Issue 2, Pages 363-371
Publisher
Springer Nature
Online
2013-12-02
DOI
10.1007/s00280-013-2361-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABT-199: Taking Dead Aim at BCL-2
- (2013) Matthew S. Davids et al. CANCER CELL
- Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes
- (2013) F Basit et al. CELL DEATH AND DIFFERENTIATION
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function
- (2012) S. M. Schoenwaelder et al. BLOOD
- Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo
- (2012) S Ackler et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- 620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors
- (2012) D.W. Rasco et al. EUROPEAN JOURNAL OF CANCER
- Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines
- (2012) Abid R. Mattoo et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
- (2012) M. Wong et al. MOLECULAR CANCER THERAPEUTICS
- The accessible chromatin landscape of the human genome
- (2012) Robert E. Thurman et al. NATURE
- Target mRNA inhibition by oligonucleotide drugs in man
- (2012) H. L. Lightfoot et al. NUCLEIC ACIDS RESEARCH
- The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein
- (2011) Meike Vogler et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
- (2011) J. Shi et al. CANCER RESEARCH
- Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models
- (2011) Nguyen Tan et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia
- (2011) Loren D. Walensky JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- An Amino Acid-based Amphoteric Liposomal Delivery System for Systemic Administration of siRNA
- (2011) Roger C Adami et al. MOLECULAR THERAPY
- RNAi-based Therapeutics Targeting Survivin and PLK1 for Treatment of Bladder Cancer
- (2011) Shaguna Seth et al. MOLECULAR THERAPY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis
- (2010) Sakuma ONCOLOGY REPORTS
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More